Neutral Solution Low in Glucose Degradation Products is Associated with Less Peritoneal Fibrosis and Vascular Sclerosis in Patients Receiving Peritoneal Dialysis
Authors:
Open Access
- 1 May 2012
- journal article
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 33 (3) , 242-251
Abstract
♦ Background: The effects of novel biocompatible peritoneal dialysis (PD) solutions on human peritoneal membrane pathology have yet to be determined. Quantitative evaluation of human peritoneal biopsy specimens may reveal the effects of the new solutions on peritoneal membrane pathology.Keywords
This publication has 29 references indexed in Scilit:
- The physiological role of endoglin in the cardiovascular systemAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysisNephrology Dialysis Transplantation, 2009
- Lymphatic vessels develop during tubulointerstitial fibrosisKidney International, 2009
- Peritoneal Angiogenesis in Response to Dialysis Fluid2009
- Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?Clinical Kidney Journal, 2008
- Impact of Uremia, Diabetes, and Peritoneal Dialysis Itself on the Pathogenesis of Peritoneal SclerosisClinical Journal of the American Society of Nephrology, 2008
- Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membraneKidney International, 2004
- Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levelsKidney International, 2001
- Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation productsKidney International, 2001
- Biocompatibility and buffers: Effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell functionKidney International, 1998